Making Sense of Benzodiazepine Results: Clinical and Practical Implications of POCT vs. Definitive Testing
Date: April 30, 2026 | Time: 9:00am (CT) and 1:00pm (CT)
Please join us for an educational webinar on benzodiazepine results hosted by Dr. Chris Burke, Pharm.D., BCPS. Dr. Burke will discuss the clinical and practical implications of Point-of-Care Testing (POCT) vs Definitive Testing.
Webinar Objectives
By the end of this session, participants will be able to:
- Review key analytical limitations of POCT benzodiazepine immunoassays, including lorazepam, clonazepam metabolites, alprazolam metabolites, and emerging/non‑traditional benzodiazepines.
- Compare POCT results with definitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) findings and explain how discordant results may influence adherence assessment, risk evaluation, and clinical decision making.
- Identify clinical scenarios in which definitive LC-MS/MS benzodiazepine testing provides added value, such as suspected non prescribed use, polysubstance risk, or patient presentations inconsistent with POCT findings.
- Apply practical strategies for incorporating definitive LC-MS/MS testing into patient care, including when to consider additional testing based on clinical judgment or limitations of immunoassay performance.
